Header image
               
Impact Factor Journals
        Innate Immune Response in Hypertension.        
                  Current Pharmaceutical Design.                
                  2023,
                
                              28(36),
                  
                              2984-2990,
                          
                  ISSN: 1381-6128,
                
                
                              PMID: 36154596,                          
                 
                          
        
      
    
        Anticancer 5-arylidene-2-(4-hydroxyphenyl)aminothiazol-4(5H)-ones as tubulin inhibitors.        
                  Archiv der Pharmazie.                
                  2022,
                
                              355(12),
                  
                              e2200419,
                          
                  ISSN: 0365-6233,
                
                
                              PMID: 36109178,                          
                 
                          
        
      
    
        The epigenetic impact of suberohydroxamic acid and 5‑Aza‑2'‑deoxycytidine on DNMT3B expression in myeloma cell lines differing in IL‑6 expression.        
                  Molecular Medicine Reports.                
                  2022,
                
                              26(4),
                  
                              321,
                          
                  ISSN: 1791-2997,
                
                
                              PMID: 36043519,                          
                 
                          
        
      
     
               
               
               
               
               
               
               
              